Literature DB >> 29632273

Outcomes and morbidities of patients who survive haemoglobin Bart's hydrops fetalis syndrome: 20-year retrospective review.

W Yk Chan1, A Wk Leung2, C W Luk3, R Ch Li4, A Sc Ling5, S Y Ha1.   

Abstract

INTRODUCTION: Haemoglobin Bart's hydrops fetalis syndrome was once considered a fatal condition. However, advances over the past two decades have enabled survival of affected patients. Data relating to their morbidities and outcomes will help medical specialists formulate a management plan and parental counselling.
METHODS: All babies with the syndrome who survived beyond the neonatal period and were subsequently managed long-term in eight public hospitals in Hong Kong from 1 January 1996 to 31 December 2015 were included. Patient and parent characteristics, antenatal care, reasons for continuation of pregnancy, intrauterine interventions, perinatal course, presence of congenital malformations, stem-cell transplantation details, and long-term neurodevelopmental outcomes were reviewed.
RESULTS: A total of nine patients were identified, of whom five were female and four male. The median follow-up duration was 7 years. All were Chinese and were homozygous for the Southeast Asian α-thalassaemia deletion. Five of the nine mothers received antenatal care at a public hospital and opted to continue the pregnancy after antenatal diagnosis and counselling. Despite intrauterine transfusions, all babies were born with respiratory depression and required intubation and mechanical ventilation during the neonatal period. Hypospadias was identified in all four male infants. Growth retardation, global developmental delay, and residual neurological deficits were noted in two-thirds of the patients. Haematopoietic stem-cell transplantation was performed in two patients, who became transfusion-independent.
CONCLUSIONS: Survival of patients with Bart's hydrops fetalis syndrome is possible but not without short- and long-term complications; local epidemiology is comparable to that documented for an international registry. Detailed antenatal counselling of parents with a non-judgemental attitude and cautious optimism are imperative.

Entities:  

Keywords:  Alpha-thalassemia; Hong Kong; Hydrops fetalis; Morbidity; Thalassemia

Mesh:

Substances:

Year:  2018        PMID: 29632273     DOI: 10.12809/hkmj176336

Source DB:  PubMed          Journal:  Hong Kong Med J        ISSN: 1024-2708            Impact factor:   2.227


  5 in total

Review 1.  Advances in the management of α-thalassemia major: reasons to be optimistic.

Authors:  Paulina Horvei; Tippi MacKenzie; Sandhya Kharbanda
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

2.  Evaluating the Clinical Utility of Genome Sequencing for Cytogenetically Balanced Chromosomal Abnormalities in Prenatal Diagnosis.

Authors:  Mullin Ho Chung Yu; Jeffrey Fong Ting Chau; Sandy Leung Kuen Au; Hei Man Lo; Kit San Yeung; Jasmine Lee Fong Fung; Christopher Chun Yu Mak; Claudia Ching Yan Chung; Kelvin Yuen Kwong Chan; Brian Hon Yin Chung; Anita Sik Yau Kan
Journal:  Front Genet       Date:  2021-01-27       Impact factor: 4.599

3.  Consensus statement for the perinatal management of patients with α thalassemia major.

Authors:  Tippi C MacKenzie; Ali Amid; Michael Angastiniotis; Craig Butler; Sandra Gilbert; Juan Gonzalez; Roberta L Keller; Sandhya Kharbanda; Melanie Kirby-Allen; Barbara A Koenig; Wade Kyono; Ashutosh Lal; Billie R Lianoglou; Mary E Norton; Keith K Ogasawara; Tachjaree Panchalee; Mara Rosner; Marisa Schwab; Alexis Thompson; John S Waye; Elliott Vichinsky
Journal:  Blood Adv       Date:  2021-12-28

Review 4.  Potential new approaches to the management of the Hb Bart's hydrops fetalis syndrome: the most severe form of α-thalassemia.

Authors:  Andrew J King; Douglas R Higgs
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

5.  Neonatal hereditary spherocytosis caused by a de novo frameshift mutation of the SPTB gene characterized by hydrops fetalis: A case report.

Authors:  Yimin Zhang; Shuming Shao; Jie Liu; Chaomei Zeng; Ye Han; Xiaorui Zhang
Journal:  Medicine (Baltimore)       Date:  2021-03-26       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.